On March 4, 2026, Xencor Inc. reported that Alexion Pharmaceuticals claims non-payment of U.S. royalties on Ultomiris sales, amounting to a projected loss of $100-$120 million until 2028, though Xencor disputes this; Xencor expects between $380-$400 million in cash by end of 2026.